文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

β-D-葡聚糖指导成人脓毒症抗真菌治疗:CandiSep随机临床试验

(1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.
PubMed 文献 · Intensive Care Med · 2022-06-16
一句话结论对侵袭性念珠菌感染高风险但实际发生率低的脓毒症患者,血清BDG指导抗真菌治疗未改善28天死亡率(33.7% vs 30.5%,RR 1.10,P=0.53)。

CandiSep为多中心随机对照试验,2016年9月至2019年9月在18个ICU纳入339例侵袭性念珠菌感染高风险的成人脓毒症患者。对照组按培养结果启动目标性抗真菌治疗;BDG组在此基础上,若研究前2天内连续两次BDG样本中至少一次≥80 pg/mL即给予抗真菌药,两组均不鼓励经验性抗真菌治疗。主要终点28天死亡率在BDG组33.7%(58/172)与对照组30.5%(51/167)间无显著差异(RR 1.10,95%CI 0.80-1.51,P=0.53);BDG组抗真菌治疗中位时间1.1天(IQR 1.0-2.2)短于对照组4.4天(IQR 2.0-9.1,P<0.01)。作者结论:BDG指导未改善28天死亡率,本研究不能评价BDG指导在更严格筛选的高危人群中的潜在获益。

要点

  • BDG组28天死亡33.7%(58/172)vs 对照组30.5%(51/167),RR 1.10(95%CI 0.80-1.51),P=0.53,无显著差异。
  • BDG组研究前96小时内48.8%(84/172)接受抗真菌治疗,对照组仅6%(10/167)。
  • BDG组抗真菌治疗中位时间1.1天(IQR 1.0-2.2)vs 对照组4.4天(IQR 2.0-9.1),P<0.01。
  • 入组后96小时内诊断侵袭性念珠菌感染者48例(14.2%),实际发生率低于预期。
  • 触发条件为研究前2天内连续两次BDG样本中至少一次≥80 pg/mL;两组均不鼓励经验性抗真菌治疗。

适用人群与场景

  • 18个ICU收治的成人脓毒症患者,且具有侵袭性念珠菌感染高风险。

诊断标准与关键阈值

  • BDG组:研究前2天内连续两次BDG样本中至少一次≥80 pg/mL即启动抗真菌治疗。
  • 对照组:按培养结果驱动的目标性抗真菌治疗。

处置流程与药物剂量

  • 两组均不鼓励经验性抗真菌治疗。
  • BDG组在目标性治疗基础上,满足BDG阈值(≥80 pg/mL)即给予抗真菌药。

研究设计与关键结果

  • 多中心随机对照试验,2016年9月至2019年9月在18个ICU纳入339例成人脓毒症患者。
  • 入组后96小时内诊断侵袭性念珠菌感染者48例(14.2%)。
  • BDG组研究前96小时内接受抗真菌治疗48.8%(84/172),对照组6%(10/167)。
  • 28天死亡:BDG组33.7%(58/172)vs 对照组30.5%(51/167),RR 1.10(95%CI 0.80-1.51),P=0.53。
  • 抗真菌治疗中位时间:BDG组1.1天(IQR 1.0-2.2)vs 对照组4.4天(IQR 2.0-9.1),P<0.01。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验。
  • 局限:作者指出本研究不能评价BDG指导在更严格筛选的高危人群中的潜在获益;实际侵袭性念珠菌感染发生率低于预期。

对床旁实践的改变

  • 对侵袭性念珠菌感染高风险但实际发生率低的脓毒症患者,血清BDG指导的抗真菌治疗未改善28天死亡率;作者认为本研究不能评价BDG指导在更严格筛选的高危人群中的潜在获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To investigate whether (1 → 3)-β-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI).

METHODS: Multicenter, randomized, controlled trial carried out between September 2016 and September 2019 in 18 intensive care units enrolling adult sepsis patients at high risk for ICI. Patients in the control group received targeted antifungal therapy driven by culture results. In addition to targeted therapy, patients in the BDG group received antifungals if at least one of two consecutive BDG samples taken during the first two study days was ≥ 80 pg/mL. Empirical antifungal therapy was discouraged in both groups. The primary endpoint was 28-day-mortality.

RESULTS: 339 patients were enrolled. ICI was diagnosed in 48 patients (14.2%) within the first 96 h after enrollment. In the BDG-group, 48.8% (84/172) patients received antifungals during the first 96 h after enrollment and 6% (10/167) patients in the control group. Death until day 28 occurred in 58 of 172 patients (33.7%) in the BDG group and 51 of 167 patients (30.5%) in the control group (relative risk 1.10; 95% confidence interval, 0.80-1.51; p = 0.53). Median time to antifungal therapy was 1.1 [interquartile range (IQR) 1.0-2.2] days in the BDG group and 4.4 (IQR 2.0-9.1, p < 0.01) days in the control group.

CONCLUSIONS: Serum BDG guided antifungal treatment did not improve 28-day mortality among sepsis patients with risk factors for but unexpected low rate of IC. This study cannot comment on the potential benefit of BDG-guidance in a more selected at-risk population.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bloos F, Held J, Kluge S, et al. (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med. 2022. PMID: 35708758. doi:10.1007/s00134-022-06733-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。